Get the Stockscreener App
16.00
8.18%
1.21
Latigo Biotherapeutics, Inc. Common Stock stock is traded at $16.00, with a volume of 184.22K.
It is up +8.18% in the last 24 hours and down -27.77% over the past month.
See More
Previous Close:
$14.79
Open:
$14.84
24h Volume:
184.22K
Relative Volume:
0.43
Market Cap:
$1.06B
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-3.79%
1M Performance:
-27.77%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$14.60
$16.89
52-Week Range:
$14.60
$25.93
Latigo Biotherapeutics, Inc. Common Stock Stock (LTGO) Company Profile
Name
Latigo Biotherapeutics, Inc. Common Stock
Sector
Industry
Phone
-
Address
-
Compare LTGO vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTGO
Latigo Biotherapeutics, Inc. Common Stock
|
16.00 | 1.06B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.05 | 129.28B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.32 | 85.56B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
765.11 | 78.77B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.60 | 51.35B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
190.95 | 40.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Latigo Biotherapeutics, Inc. Common Stock Stock (LTGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-26 | Initiated | Goldman | Buy |
| Sep-01-26 | Initiated | Guggenheim | Buy |
| Sep-01-26 | Initiated | Jefferies | Buy |
| Sep-01-26 | Initiated | Leerink Partners | Outperform |
Latigo Biotherapeutics, Inc. Common Stock Stock (LTGO) Latest News
Latigo Biotherapeutics, Inc. Common Stock (NASDAQ: LTGO) Stock Price, News & Analysis - kalkine.ca
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
Latigo Biotherapeutics Q2 Results: EPS loss narrows 24% YoY - scanx.trade
Latigo Biotherapeutics (LTGO) draws 4.45M-share stake from Deep Track - Stock Titan
Sanofi Converts Series B Preferred Stock and Convertible Note into Latigo Biotherapeutics Common Shares Following IPO - Kalkine Media
Latigo Biotherapeutics Completes IPO and Updates Governance - TipRanks
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued - Yahoo Finance
Latigo Biotherapeutics (Nasdaq:LTGO)Stock Analysis - Simply Wall Street
Latigo Biotherapeutics Prices Upsized $345.6 Million Initial Public Offering - quiverquant.com
Latham & Watkins Advises on Latigo Biotherapeutics’ Upsized US$345.6 Million Initial Public Offering - Latham & Watkins LLP
Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering - GlobeNewswire
Latigo Biotherapeutics prices $345.6M IPO at $18 per share - Investing.com
Latigo Biotherapeutics files for Nasdaq IPO at up to $18 per share - Investing.com
Latigo Biotherapeutics files for $256M-$288M Nasdaq IPO - scanx.trade
Latigo Biotherapeutics Commences IPO Process For Pain Treatment Pipeline (Pending:LTGO) - Seeking Alpha
Latigo Biotherapeutics, Inc. Common Stock Stock (LTGO) Financials Data
There is no financial data for Latigo Biotherapeutics, Inc. Common Stock (LTGO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Latigo Biotherapeutics, Inc. Common Stock Stock (LTGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
Aug 10 '26 |
Buy |
18.00 |
140,000 |
2,520,000 |
2,008,024 |
6.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):